ACRS Q3 2020 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

$407M

Q3 2020 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$1M+47.4% YoY

Gross Profit

$260,00017.9% margin

Operating Income

-$10M-722.2% margin

Net Income

-$11M-735.6% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

-29.2%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$72M

Total Liabilities

$31M

Stockholders' Equity

$41M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$983,000	+47.4%
Gross Profit	$260,000	$157,000	+65.6%
Operating Income	-$10M	-$23M	+54.2%
Net Income	-$11M	-$55M	+80.7%

Revenue Segments

Laboratory Research Revenue

$1M92%

Other Revenue

$118,0008%